TrialThe Lancet. Oncology2017

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Alice T Shaw et al.PubMed ↗Publisher ↗

No numbers read from the abstract.